TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:59
NewAmsterdam Pharma Co N.V. ( NAMS ) https://www.newamsterdampharma.com
22.72USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Netherlands
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
NAMS
71.08%
SPY
32.74%
NAMS
131.84%
SPY
92.93%
NAMS
0.00%
SPY
224.41%
NAMS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1873.71
1533.26
0.33
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
810.05
19.61
6.50
-1.13
0.00
-123.86
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-8.33
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-2.52
-1.43
0.00
Other Earnings and Cash Flow Stats:
NewAmsterdam Pharma Co N.V. ( NAMS ) Net Income TTM ($MM) is 15.27
NewAmsterdam Pharma Co N.V. ( NAMS ) Operating Income TTM ($MM) is 17.50
NewAmsterdam Pharma Co N.V. ( NAMS ) Owners' Earnings Annual ($MM) is 0.00
NewAmsterdam Pharma Co N.V. ( NAMS ) Current Price to Owners' Earnings ratio is 0.00
NewAmsterdam Pharma Co N.V. ( NAMS ) EBITDA TTM ($MM) is 17.51
NewAmsterdam Pharma Co N.V. ( NAMS ) EBITDA Margin is 0.00%
Capital Allocation:
NewAmsterdam Pharma Co N.V. ( NAMS ) has paid 0.00 dividends per share and bought back -0.909988 million shares in the past 12 months
NewAmsterdam Pharma Co N.V. ( NAMS ) has reduced its debt by 0.126 million USD in the last 12 months
Capital Structure:
NewAmsterdam Pharma Co N.V. ( NAMS ) Interest-bearing Debt ($MM) as of last quarter is 0
NewAmsterdam Pharma Co N.V. ( NAMS ) Annual Working Capital Investments ($MM) are 2
NewAmsterdam Pharma Co N.V. ( NAMS ) Book Value ($MM) as of last quarter is 288
NewAmsterdam Pharma Co N.V. ( NAMS ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
NewAmsterdam Pharma Co N.V. ( NAMS ) has 340 million in cash on hand as of last quarter
NewAmsterdam Pharma Co N.V. ( NAMS ) has 49 million of liabilities due within 12 months, and long term debt 0 as of last quarter
NewAmsterdam Pharma Co N.V. ( NAMS ) has 82 common shares outstanding as of last quarter
NewAmsterdam Pharma Co N.V. ( NAMS ) has 0 million USD of preferred stock value
Academic Scores:
NewAmsterdam Pharma Co N.V. ( NAMS ) Altman Z-Score is 18.78 as of last quarter
NewAmsterdam Pharma Co N.V. ( NAMS ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
NewAmsterdam Pharma Co N.V. ( NAMS ) largest shareholder is owning shares at 0.00 ($MM) value
Louis G Lange(an insider) Bought 5000 shares of NewAmsterdam Pharma Co N.V. ( NAMS ) for the amount of $95000.00 on 2024-02-13
7.07% of NewAmsterdam Pharma Co N.V. ( NAMS ) is held by insiders, and 87.05% is held by institutions
NewAmsterdam Pharma Co N.V. ( NAMS ) went public on 2022-11-23
Other NewAmsterdam Pharma Co N.V. ( NAMS ) financial metrics:
FCF:-24.66
Unlevered Free Cash Flow:5.14
EPS:-0.07
Operating Margin:-8.33
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-1.36
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About NewAmsterdam Pharma Co N.V. ( NAMS ) :
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.